SPHK1 and glioblastoma: Blockage of ATF4-SPHK1 signaling inhibited GBM cell invasion and TMZ resistance in vitro and in vivo, suggesting that TMZ therapy in combination of inhibition of SPHK1-ATF4 signaling could be a therapeutic strategy to overcome TMZ resistance in GBM patients.